Terug

Watch Compare

Regen BioPharma Inc

Datakwaliteit: 100%

Ook genoteerd als RGBPP OTC

RGBP

OTC Manufacturing Chemicals

€ 0,00

€ 0,00 (0,00%)

Marktkapitalisatie: 106.159,0

Prijs

€ 0,00

Marktkapitalisatie

106.159,0

Dagbereik

—

52-Weeksbereik

—

Volume

—

Openen —

50D / 200D Gem.

—

50D / 200D Gem.

—

Quick Summary

Belangrijkste Punten

Revenue grew 40,22% annually over 5 years — strong growth

Negative free cash flow of -515.153,0

Revenue growth is decelerating — 1Y growth trails 5Y average by 40,22%

Groei

Revenue Growth (5Y)

40,22%

Boven sectorgemiddelde (1,82%)

Revenue (1Y)0,00%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Kwaliteit

Return on Equity

N/A

ROICN/A

Net Margin-730,03%

Op. Margin-350,35%

Veiligheid

Debt / Equity

N/A

Current Ratio0,03

Interest Coverage-5,20

Waardering

PE (TTM)

-0,06

Boven sectorgemiddelde (-1,48)

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)

Metriek	Aandeel	Sector Mediaan
P/E	-0,1	-1,5
P/B	—	1,6
ROE %	—	-53,5
Net Margin %	-730,0	-41,5
Rev Growth 5Y %	40,2	1,8
D/E	—	0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode	WPA Sch.	Omzet Sch.	Analisten
FY2026	—	331.704,78	—

All Fundamental Metrics

Growth
Revenue Growth (1Y)	0,00%	Revenue Growth (3Y)	36,72%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	40,22%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	236.561,0	Net Income (TTM)	-1,73 M
ROE	N/A	ROA	-795,99%
Gross Margin	N/A	Operating Margin	-350,35%
Net Margin	-730,03%	Free Cash Flow (TTM)	-515.153,0
ROIC	N/A	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	0,03
Interest Coverage	-5,20	Asset Turnover	1,09
Working Capital	-6,57 M	Tangible Book Value	-6,57 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0,06	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	0,45
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-485,27%
Market Cap	106.159,0	Enterprise Value	101.581,0
Per Share
EPS (Diluted TTM)	0,07	Revenue / Share	0,00
FCF / Share	0,00	OCF / Share	0,00
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	29,83%
SBC-Adj. FCF	N/A	Growth Momentum	-40,22

Income Statement

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	236.561,0	236.560,0	126.560,0	125.517,0	61.194,0
Net Income	-1,27 M	-668.255,0	1,16 M	2,44 M	-6,77 M
EPS (Diluted)	-0,05	-0,16	0,29	—	—
Gross Profit	—	—	—	—	—
Operating Income	-338.540,0	-417.221,0	-686.950,0	-339.605,0	-200.771,0
EBITDA	—	—	—	—	—
R&D Expenses	11.725,0	153.685,0	212.297,0	158.138,0	36.704,0
SG&A Expenses	—	—	—	—	—
D&A	—	—	—	—	—
Interest Expense	158.286,0	72.445,0	58.584,0	138.720,0	316.013,0
Income Tax	0,0	—	—	—	—

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	274.628,0	161.084,0	353.617,0	559.002,0	1,21 M
Total Liabilities	6,56 M	5,38 M	5,46 M	8,60 M	14,70 M
Shareholders' Equity	-6,28 M	-5,22 M	-5,10 M	-8,04 M	-13,49 M
Total Debt	—	—	—	—	—
Cash & Equivalents	69.555,0	716,0	—	51.204,0	727.162,0
Current Assets	274.628,0	143.351,0	131.037,0	336.422,0	994.124,0
Current Liabilities	6,56 M	5,38 M	5,31 M	8,60 M	14,70 M